(Q44279417)

1 December 2017

title

Use of β-blockers is associated with prostate cancer-specific survival in prostate cancer patients on androgen deprivation therapy (English)

1 reference

1 December 2017

1 reference

Morten Wang Fagerland

2

object named as

Morten Wang Fagerland

1 reference

1 December 2017

3

Sophie D Fosså

1 reference

1 December 2017

author name string

Helene Hartvedt Grytli

1

1 reference

1 December 2017

Kristin Austlid Taskén

4

1 reference

1 December 2017

Lise Lund Håheim

5

1 reference

1 December 2017

language of work or name

1 reference

20 July 2012

1 reference

1 December 2017

1 reference

1 December 2017

volume

73

1 reference

1 December 2017

issue

3

1 reference

1 December 2017

page(s)

250-260

1 reference

"Getting from here to there"--mechanisms and limitations to the activation of the androgen receptor in castration-resistant prostate cancer

1 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22564

Roles of cAMP and cAMP-dependent protein kinase in the progression of prostate cancer: Cross-talk with the androgen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22564

Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22564

The norepinephrine-driven metastasis development of PC-3 human prostate cancer cells in BALB/c nude mice is inhibited by beta-blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22564

Molecular pathways: beta-adrenergic signaling in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22564

Norepinephrine antagonists and cancer risk.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22564

Antihypertensive drug use and the risk of prostate cancer (Canada)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22564

Incidence of and mortality from cancer in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22564

Association between captopril, other antihypertensive drugs and risk of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22564

Androgen dependent regulation of protein kinase A subunits in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22564

Hormonal regulation of beta2-adrenergic receptor level in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22564

Does β-adrenoceptor blocker therapy improve cancer survival? Findings from a population-based retrospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22564

Risk factors associated with body mass index increase in men at 28 years follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22564

Initial management of prostate cancer: first year experience with the Norwegian National Prostate Cancer Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22564

Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22564

β-Blockers and survival among Danish patients with malignant melanoma: a population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22564

Blood pressure and risk of prostate cancer: Cohort Norway (CONOR).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22564

Blood pressure, body size and prostate cancer risk in the Swedish Construction Workers cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22564

Data quality at the Cancer Registry of Norway: an overview of comparability, completeness, validity and timeliness

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22564

EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22564

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22564

Type of diabetes mellitus and the odds of Gleason score 8 to 10 prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22564

Potential for prostate cancer prevention through physical activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22564

Cardiovascular drug class specificity: beta-blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22564

Long-term use of antihypertensive drugs and risk of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22564

21 January 2018

Identifiers

DOI

10.1002/PROS.22564

1 reference

1 December 2017

1 reference